Epclusa Shortage Update: What Patients Need to Know in 2026

If you're trying to fill an Epclusa prescription and hitting dead ends, you might be wondering: is there an official shortage? The short answer is no — but the real picture is more complicated. Here's everything you need to know about Epclusa availability in 2026.

Current Epclusa Shortage Status (2026)

As of 2026, Epclusa (sofosbuvir/velpatasvir) is NOT listed on the FDA Drug Shortage Database and is NOT listed by the American Society of Health-System Pharmacists (ASHP) as a current shortage. Gilead Sciences, the manufacturer, has not reported any supply disruptions or manufacturing issues.

However, patients across the country continue to report difficulty filling their prescriptions. This is a real and frustrating access problem — it's just not a shortage in the traditional manufacturing sense. Understanding why this happens is the first step toward finding a solution.

Why Are Patients Still Having Trouble Finding Epclusa?

The access challenges patients face with Epclusa in 2026 are driven by a combination of factors:

• High price creates stocking reluctance. The brand-name list price of approximately $24,350 for a 28-day supply means most retail pharmacies don't stock it proactively. They order it on a patient-by-patient basis once they have a confirmed, insurance-approved prescription.
• Prior authorization is nearly universal. Commercial plans, Medicare Part D, and even many Medicaid programs require prior authorization before covering Epclusa. These approvals can take days to weeks.
• Specialty pharmacy routing. Many plans only cover Epclusa when dispensed through specific specialty pharmacies, not retail chains. Patients who don't know this can spend significant time at the wrong pharmacy.
• Step therapy requirements. Some insurers require patients to try Mavyret (a lower-cost alternative) before approving Epclusa. This can delay treatment for weeks while the step therapy process plays out.

Epclusa Price and Availability Snapshot for 2026

Here's the current pricing landscape for Epclusa in 2026:

• Brand Epclusa list price: ~$24,350 for 28 tablets (approximately $78,000 for a full 12-week course)
• Authorized generic (Asegua Therapeutics): ~$6,728 for 28 tablets
• Commercial insurance copay: Typically less than $250/month; as low as $5/month with Gilead's co-pay savings card
• Medicaid: $0–$5/month in most state programs
• Medicare Part D: Covered; 2026 Part D out-of-pocket cap is $2,100/year

What the Authorized Generic Means for Patients

Gilead Sciences released an authorized generic of Epclusa through its affiliate Asegua Therapeutics. This version contains the identical active ingredients (sofosbuvir 400 mg/velpatasvir 100 mg) and has the same safety and efficacy profile. The list price is significantly lower (~$6,728 vs. ~$24,350 for 28 tablets), making it more accessible for some patients.

Ask your pharmacy specifically about the authorized generic if cost is a barrier — some pharmacies stock this version rather than the brand-name Epclusa.

Generic Epclusa: When Will True Generics Be Available?

Based on current patent protections, true third-party generics for Epclusa are not expected to enter the US market until approximately July 2034. Sixteen patents protect Epclusa in the US, and while there have been 20 patent litigation cases suggesting interest from generic manufacturers, no independent generics are currently FDA-approved for the US market.

What Should Patients Do Right Now?

If you're struggling to access Epclusa in 2026, here are your best options:

1. Confirm your prior authorization is approved or appeal a denial with your provider's help
2. Ask your pharmacy to place a special order (most can receive it within 1-3 days)
3. Check if your plan requires a specialty pharmacy and identify which ones are in-network
4. Use medfinder to search nearby pharmacies — we call them so you don't have to
5. Contact Gilead Support Path at 1-855-769-7284 for financial assistance and pharmacy navigation

Keep Watching: What Could Change in 2026

Formulary changes and Medicaid policy updates can affect Epclusa access throughout the year. If your access situation changes, revisit your options including alternatives to Epclusa that your doctor can prescribe. The most important thing is not to delay treatment — hepatitis C causes ongoing liver damage, and every week without treatment matters.